Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the global life sciences industry, was recently the focus of a publication by Zacks Small Cap Research titled “PBIO: Enters Biopharmaceutical Quality Control Market”. The publication follows the company’s December 20 announcement regarding the release of redesigned software for its Barocycler 2320EXTREME instrument. The publication notes that the new software was created through collaboration with the company’s biopharmaceutical company customers, therefore entering PBIO into the biopharmaceutical market and accelerating the company’s revenue growth. The Zacks report also discusses PBIO recently acquiring all assets of BaroFold, Inc. The company announced the acquisition of assets including all patents, equipment, and intellectual property (“IP”) relating to BaroFold’s PreEMT™ high-pressure protein refolding technology on December 13. The acquired technology is complimentary to PBIO’s proprietary Pressure Cycling Technology (“PCT”), increasing the company’s IP in high-pressure technologies. Among other highlights, Zacks noted that this grants the company the ability to operate in several important areas for biologics research and manufacturing.
To read the full press release, visit http://dtn.fm/Bun13
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. PBI’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of the company’s patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
